TY - JOUR AU - Jemal, A. AU - Bray, F. AU - Center, M. M. AU - Ferlay, J. AU - Ward, E. AU - Forman, D. PY - 2011 DA - 2011// TI - Global cancer statistics JO - CA Cancer J Clin VL - 61 UR - https://doi.org/10.3322/caac.20107 DO - 10.3322/caac.20107 ID - Jemal2011 ER - TY - JOUR AU - Hartwell, L. H. AU - Culotti, J. AU - Reid, B. PY - 1970 DA - 1970// TI - Genetic control of the cell-division cycle in yeast. I. Detection of mutants JO - Proc Natl Acad Sci U S A VL - 66 UR - https://doi.org/10.1073/pnas.66.2.352 DO - 10.1073/pnas.66.2.352 ID - Hartwell1970 ER - TY - JOUR AU - Nurse, P. PY - 2012 DA - 2012// TI - Finding CDK: linking yeast with humans JO - Nat Cell Biol VL - 14 UR - https://doi.org/10.1038/ncb2547 DO - 10.1038/ncb2547 ID - Nurse2012 ER - TY - JOUR AU - Evans, T. AU - Rosenthal, E. T. AU - Youngblom, J. AU - Distel, D. AU - Hunt, T. PY - 1983 DA - 1983// TI - Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division JO - Cell VL - 33 UR - https://doi.org/10.1016/0092-8674(83)90420-8 DO - 10.1016/0092-8674(83)90420-8 ID - Evans1983 ER - TY - JOUR AU - Arnold, A. AU - Papanikolaou, A. PY - 2005 DA - 2005// TI - Cyclin D1 in breast cancer pathogenesis JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.05.064 DO - 10.1200/JCO.2005.05.064 ID - Arnold2005 ER - TY - JOUR AU - Yu, Q. AU - Sicinska, E. AU - Geng, Y. AU - Ahnström, M. AU - Zagozdzon, A. AU - Kong, Y. PY - 2006 DA - 2006// TI - Requirement for CDK4 kinase function in breast cancer JO - Cancer Cell VL - 9 UR - https://doi.org/10.1016/j.ccr.2005.12.012 DO - 10.1016/j.ccr.2005.12.012 ID - Yu2006 ER - TY - JOUR AU - Landis, M. W. AU - Pawlyk, B. S. AU - Li, T. AU - Sicinski, P. AU - Hinds, P. W. PY - 2006 DA - 2006// TI - Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis JO - Cancer Cell VL - 9 UR - https://doi.org/10.1016/j.ccr.2005.12.019 DO - 10.1016/j.ccr.2005.12.019 ID - Landis2006 ER - TY - JOUR AU - Finn, R. S. AU - Dering, J. AU - Conklin, D. AU - Kalous, O. AU - Cohen, D. J. AU - Desai, A. J. PY - 2009 DA - 2009// TI - PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro JO - Breast Cancer Res VL - 11 UR - https://doi.org/10.1186/bcr2419 DO - 10.1186/bcr2419 ID - Finn2009 ER - TY - JOUR AU - Finn, R. S. AU - Crown, J. P. AU - Lang, I. AU - Boer, K. AU - Bondarenko, I. M. AU - Kulyk, S. O. PY - 2012 DA - 2012// TI - Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC) JO - Cancer Res VL - 72 ID - Finn2012 ER - TY - JOUR AU - Choi, Y. J. AU - Anders, L. PY - 2014 DA - 2014// TI - Signaling through cyclin D-dependent kinases JO - Oncogene VL - 33 UR - https://doi.org/10.1038/onc.2013.137 DO - 10.1038/onc.2013.137 ID - Choi2014 ER - TY - JOUR AU - Malumbres, M. AU - Barbacid, M. PY - 2009 DA - 2009// TI - Cell cycle, CDKs and cancer: a changing paradigm JO - Nat Rev Cancer VL - 9 UR - https://doi.org/10.1038/nrc2602 DO - 10.1038/nrc2602 ID - Malumbres2009 ER - TY - JOUR AU - Morgan, D. O. PY - 1997 DA - 1997// TI - Cyclin-dependent kinases: engines, clocks, and microprocessors JO - Annu Rev Cell Dev Biol VL - 13 UR - https://doi.org/10.1146/annurev.cellbio.13.1.261 DO - 10.1146/annurev.cellbio.13.1.261 ID - Morgan1997 ER - TY - JOUR AU - Canavese, M. AU - Santo, L. AU - Raje, N. PY - 2012 DA - 2012// TI - Cyclin dependent kinases in cancer: potential for therapeutic intervention JO - Cancer Biol Ther VL - 13 UR - https://doi.org/10.4161/cbt.19589 DO - 10.4161/cbt.19589 ID - Canavese2012 ER - TY - JOUR AU - Musgrove, E. A. PY - 2006 DA - 2006// TI - Cyclins: roles in mitogenic signaling and oncogenic transformation JO - Growth Factors VL - 24 UR - https://doi.org/10.1080/08977190500361812 DO - 10.1080/08977190500361812 ID - Musgrove2006 ER - TY - JOUR AU - Bertoli, C. AU - Skotheim, J. M. AU - Bruin, R. A. M. PY - 2013 DA - 2013// TI - Control of cell cycle transcription during G1 and S phases JO - Nat Rev Mol Cell Biol VL - 14 UR - https://doi.org/10.1038/nrm3629 DO - 10.1038/nrm3629 ID - Bertoli2013 ER - TY - JOUR AU - Skotheim, J. M. AU - Talia, S. AU - Siggia, E. D. AU - Cross, F. R. PY - 2008 DA - 2008// TI - Positive feedback of G1 cyclins ensures coherent cell cycle entry JO - Nature VL - 454 UR - https://doi.org/10.1038/nature07118 DO - 10.1038/nature07118 ID - Skotheim2008 ER - TY - JOUR AU - Doncic, A. AU - Falleur-Fettig, M. AU - Skotheim, J. M. PY - 2011 DA - 2011// TI - Distinct interactions select and maintain a specific cell fate JO - Mol Cell VL - 43 UR - https://doi.org/10.1016/j.molcel.2011.06.025 DO - 10.1016/j.molcel.2011.06.025 ID - Doncic2011 ER - TY - JOUR AU - Aggarwal, P. AU - Vaites, L. P. AU - Kim, J. K. AU - Mellert, H. AU - Gurung, B. AU - Nakagawa, H. PY - 2010 DA - 2010// TI - Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase JO - Cancer Cell VL - 18 UR - https://doi.org/10.1016/j.ccr.2010.08.012 DO - 10.1016/j.ccr.2010.08.012 ID - Aggarwal2010 ER - TY - JOUR AU - Zhang, L. AU - Fried, F. B. AU - Guo, H. AU - Friedman, A. D. PY - 2008 DA - 2008// TI - Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation JO - Blood VL - 111 UR - https://doi.org/10.1182/blood-2007-08-109702 DO - 10.1182/blood-2007-08-109702 ID - Zhang2008 ER - TY - JOUR AU - Shen, R. AU - Wang, X. AU - Drissi, H. AU - Liu, F. AU - O’Keefe, R. J. AU - Chen, D. PY - 2006 DA - 2006// TI - Cyclin D1-cdk4 induce runx2 ubiquitination and degradation JO - J Biol Chem VL - 281 UR - https://doi.org/10.1074/jbc.M603439200 DO - 10.1074/jbc.M603439200 ID - Shen2006 ER - TY - JOUR AU - Matsuura, I. AU - Denissova, N. G. AU - Wang, G. AU - He, D. AU - Long, J. AU - Liu, F. PY - 2004 DA - 2004// TI - Cyclin-dependent kinases regulate the antiproliferative function of Smads JO - Nature VL - 430 UR - https://doi.org/10.1038/nature02650 DO - 10.1038/nature02650 ID - Matsuura2004 ER - TY - JOUR AU - Liu, E. AU - Li, X. AU - Yan, F. AU - Zhao, Q. AU - Wu, X. PY - 2004 DA - 2004// TI - Cyclin-dependent kinases phosphorylate human Cdt1 and induce its degradation JO - J Biol Chem VL - 279 UR - https://doi.org/10.1074/jbc.C300549200 DO - 10.1074/jbc.C300549200 ID - Liu2004 ER - TY - JOUR AU - Manenti, S. AU - Yamauchi, E. AU - Sorokine, O. AU - Knibiehler, M. AU - Dorsselaer, A. AU - Taniguchi, H. PY - 1999 DA - 1999// TI - Phosphorylation of the myristoylated protein kinase C substrate MARCKS by the cyclin E-cyclin-dependent kinase 2 complex in vitro JO - Biochem J VL - 340 ID - Manenti1999 ER - TY - JOUR AU - Anders, L. AU - Ke, N. AU - Hydbring, P. AU - Choi, Y. J. AU - Widlund, H. R. AU - Chick, J. M. PY - 2011 DA - 2011// TI - A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells JO - Cancer Cell VL - 20 UR - https://doi.org/10.1016/j.ccr.2011.10.001 DO - 10.1016/j.ccr.2011.10.001 ID - Anders2011 ER - TY - JOUR AU - Baker, S. J. AU - Reddy, E. P. PY - 2012 DA - 2012// TI - CDK4: a key player in the cell cycle, development, and cancer JO - Genes Cancer VL - 3 UR - https://doi.org/10.1177/1947601913478972 DO - 10.1177/1947601913478972 ID - Baker2012 ER - TY - JOUR AU - Blain, S. W. PY - 2008 DA - 2008// TI - Switching cyclin D-Cdk4 kinase activity on and off JO - Cell Cycle VL - 7 UR - https://doi.org/10.4161/cc.7.7.5637 DO - 10.4161/cc.7.7.5637 ID - Blain2008 ER - TY - JOUR AU - Carlson, M. E. AU - Hsu, M. AU - Conboy, I. M. PY - 2008 DA - 2008// TI - Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells JO - Nature VL - 454 UR - https://doi.org/10.1038/nature07034 DO - 10.1038/nature07034 ID - Carlson2008 ER - TY - JOUR AU - Cariou, S. AU - Donovan, J. C. AU - Flanagan, W. M. AU - Milic, A. AU - Bhattacharya, N. AU - Slingerland, J. M. PY - 2000 DA - 2000// TI - Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells JO - Proc Natl Acad Sci U S A VL - 97 UR - https://doi.org/10.1073/pnas.160016897 DO - 10.1073/pnas.160016897 ID - Cariou2000 ER - TY - JOUR AU - Kim, W. Y. AU - Sharpless, N. E. PY - 2006 DA - 2006// TI - The regulation of INK4/ARF in cancer and aging JO - Cell VL - 127 UR - https://doi.org/10.1016/j.cell.2006.10.003 DO - 10.1016/j.cell.2006.10.003 ID - Kim2006 ER - TY - JOUR AU - Kuilman, T. AU - Michaloglou, C. AU - Mooi, W. J. AU - Peeper, D. S. PY - 2010 DA - 2010// TI - The essence of senescence JO - Genes Dev VL - 24 UR - https://doi.org/10.1101/gad.1971610 DO - 10.1101/gad.1971610 ID - Kuilman2010 ER - TY - JOUR AU - Bienvenu, F. AU - Jirawatnotai, S. AU - Elias, J. E. AU - Meyer, C. A. AU - Mizeracka, K. AU - Marson, A. PY - 2010 DA - 2010// TI - Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen JO - Nature VL - 463 UR - https://doi.org/10.1038/nature08684 DO - 10.1038/nature08684 ID - Bienvenu2010 ER - TY - JOUR AU - Lamb, J. AU - Ramaswamy, S. AU - Ford, H. L. AU - Contreras, B. AU - Martinez, R. V. AU - Kittrell, F. S. PY - 2003 DA - 2003// TI - A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer JO - Cell VL - 114 UR - https://doi.org/10.1016/S0092-8674(03)00570-1 DO - 10.1016/S0092-8674(03)00570-1 ID - Lamb2003 ER - TY - JOUR AU - Fu, M. AU - Rao, M. AU - Bouras, T. AU - Wang, C. AU - Wu, K. AU - Li, Z. PY - 2005 DA - 2005// TI - Molecular basis of cell and developmental biology: cyclin D1 inhibits peroxisome proliferator-activated receptor γ-mediated adipogenesis through histone deacetylase recruitment JO - J Biol Chem VL - 280 UR - https://doi.org/10.1074/jbc.M500403200 DO - 10.1074/jbc.M500403200 ID - Fu2005 ER - TY - JOUR AU - Musgrove, E. A. AU - Caldon, C. E. AU - Barraclough, J. AU - Stone, A. AU - Sutherland, R. L. PY - 2011 DA - 2011// TI - Cyclin D as a therapeutic target in cancer JO - Nat Rev Cancer VL - 11 UR - https://doi.org/10.1038/nrc3090 DO - 10.1038/nrc3090 ID - Musgrove2011 ER - TY - JOUR AU - Li, Z. AU - Jiao, X. AU - Wang, C. AU - Shirley, L. AU - Elsaleh, H. PY - 2010 DA - 2010// TI - Alternative cyclin D1 splice forms differentially regulate the DNA damage response JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-0312 DO - 10.1158/0008-5472.CAN-10-0312 ID - Li2010 ER - TY - JOUR AU - Li, Z. AU - Wang, C. AU - Jiao, X. AU - Katiyar, S. AU - Casimiro, M. C. AU - Prendergast, G. C. PY - 2008 DA - 2008// TI - Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration JO - J Biol Chem VL - 283 UR - https://doi.org/10.1074/jbc.M706992200 DO - 10.1074/jbc.M706992200 ID - Li2008 ER - TY - JOUR AU - Berthet, C. AU - Aleem, E. AU - Coppola, V. AU - Tessarollo, L. AU - Kaldis, P. PY - 2003 DA - 2003// TI - Cdk2 knockout mice are viable JO - Curr Biol VL - 13 UR - https://doi.org/10.1016/j.cub.2003.09.024 DO - 10.1016/j.cub.2003.09.024 ID - Berthet2003 ER - TY - JOUR AU - Ye, X. AU - Zhu, C. AU - Harper, J. W. PY - 2001 DA - 2001// TI - A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene JO - Proc Natl Acad Sci U S A VL - 98 UR - https://doi.org/10.1073/pnas.98.4.1682 DO - 10.1073/pnas.98.4.1682 ID - Ye2001 ER - TY - JOUR AU - Hu, M. G. AU - Deshpande, A. AU - Enos, M. AU - Mao, D. AU - Hinds, E. A. AU - Hu, G. PY - 2009 DA - 2009// TI - A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-2473 DO - 10.1158/0008-5472.CAN-08-2473 ID - Hu2009 ER - TY - JOUR AU - Tsutsui, T. AU - Hesabi, B. AU - Moons, D. S. AU - Pandolfi, P. P. AU - Hansel, K. S. AU - Koff, A. PY - 1999 DA - 1999// TI - Targeted disruption of CDK4 delays cell cycle entry with enhanced p27Kip1 activity JO - Mol Cell Biol VL - 19 UR - https://doi.org/10.1128/MCB.19.10.7011 DO - 10.1128/MCB.19.10.7011 ID - Tsutsui1999 ER - TY - JOUR AU - Kozar, K. AU - Ciemerych, M. A. AU - Rebel, V. I. AU - Shigematsu, H. AU - Zagozdzon, A. AU - Sicinska, E. PY - 2004 DA - 2004// TI - Mouse development and cell proliferation in the absence of D-cyclins JO - Cell VL - 118 UR - https://doi.org/10.1016/j.cell.2004.07.025 DO - 10.1016/j.cell.2004.07.025 ID - Kozar2004 ER - TY - JOUR AU - Malumbres, M. AU - Sotillo, R. AU - Santamaría, D. AU - Galán, J. AU - Cerezo, A. AU - Ortega, S. PY - 2004 DA - 2004// TI - Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6 JO - Cell VL - 118 UR - https://doi.org/10.1016/j.cell.2004.08.002 DO - 10.1016/j.cell.2004.08.002 ID - Malumbres2004 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Bartkova, J. AU - Lukas, J. AU - Müller, H. AU - Lützhøft, D. AU - Strauss, M. AU - Bartek, J. PY - 1994 DA - 1994// TI - Cyclin D1 protein expression and function in human breast cancer JO - Int J Cancer VL - 57 UR - https://doi.org/10.1002/ijc.2910570311 DO - 10.1002/ijc.2910570311 ID - Bartkova1994 ER - TY - JOUR AU - Dickson, C. AU - Fantl, V. AU - Gillett, C. AU - Brookes, S. AU - Bartek, J. AU - Smith, R. PY - 1995 DA - 1995// TI - Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer JO - Cancer Lett VL - 90 UR - https://doi.org/10.1016/0304-3835(94)03676-A DO - 10.1016/0304-3835(94)03676-A ID - Dickson1995 ER - TY - JOUR AU - Yu, Q. AU - Geng, Y. AU - Sicinski, P. PY - 2001 DA - 2001// TI - Specific protection against breast cancers by cyclin D1 ablation JO - Nature VL - 411 UR - https://doi.org/10.1038/35082500 DO - 10.1038/35082500 ID - Yu2001 ER - TY - JOUR AU - Choi, Y. J. AU - Li, X. AU - Hydbring, P. AU - Sanda, T. AU - Stefano, J. AU - Christie, A. L. PY - 2012 DA - 2012// TI - The requirement for cyclin D function in tumor maintenance JO - Cancer Cell VL - 22 UR - https://doi.org/10.1016/j.ccr.2012.09.015 DO - 10.1016/j.ccr.2012.09.015 ID - Choi2012 ER - TY - JOUR AU - Zhang, Q. AU - Sakamoto, K. AU - Liu, C. AU - Triplett, A. AU - Lin, W. PY - 2011 DA - 2011// TI - Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-1783 DO - 10.1158/0008-5472.CAN-11-1783 ID - Zhang2011 ER - TY - JOUR AU - Reddy, H. K. D. L. AU - Mettus, R. V. AU - Rane, S. G. AU - Graña, X. AU - Litvin, J. AU - Reddy, E. P. PY - 2005 DA - 2005// TI - Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-05-2639 DO - 10.1158/0008-5472.CAN-05-2639 ID - Reddy2005 ER - TY - JOUR AU - An, H. X. AU - Beckmann, M. W. AU - Reifenberger, G. AU - Bender, H. G. AU - Niederacher, D. PY - 1999 DA - 1999// TI - Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation JO - Am J Pathol VL - 154 UR - https://doi.org/10.1016/S0002-9440(10)65257-1 DO - 10.1016/S0002-9440(10)65257-1 ID - An1999 ER - TY - JOUR AU - Buckley, M. F. AU - Sweeney, K. J. AU - Hamilton, J. A. AU - Sini, R. L. AU - Manning, D. L. AU - Nicholson, R. I. PY - 1993 DA - 1993// TI - Expression and amplification of cyclin genes in human breast cancer JO - Oncogene VL - 8 ID - Buckley1993 ER - TY - JOUR PY - 2012 DA - 2012// TI - Comprehensive molecular portraits of human breast tumours JO - Nature VL - 490 UR - https://doi.org/10.1038/nature11412 DO - 10.1038/nature11412 ID - ref52 ER - TY - JOUR AU - Tinoco, G. AU - Warsch, S. AU - Glück, S. AU - Avancha, K. AU - Montero, A. J. PY - 2013 DA - 2013// TI - Treating breast cancer in the 21st century: emerging biological therapies JO - J Cancer VL - 4 UR - https://doi.org/10.7150/jca.4925 DO - 10.7150/jca.4925 ID - Tinoco2013 ER - TY - JOUR AU - Varma, H. AU - Skildum, A. J. AU - Conrad, S. E. PY - 2007 DA - 2007// TI - Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells JO - PLoS One VL - 2 UR - https://doi.org/10.1371/journal.pone.0001256 DO - 10.1371/journal.pone.0001256 ID - Varma2007 ER - TY - JOUR AU - Sutherland, R. L. AU - Green, M. D. AU - Hall, R. E. AU - Reddel, R. R. AU - Taylor, I. W. PY - 1983 DA - 1983// TI - Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle JO - Eur J Cancer Clin Oncol VL - 19 UR - https://doi.org/10.1016/0277-5379(83)90177-3 DO - 10.1016/0277-5379(83)90177-3 ID - Sutherland1983 ER - TY - JOUR AU - Carroll, J. S. AU - Prall, O. W. AU - Musgrove, E. A. AU - Sutherland, R. L. PY - 2000 DA - 2000// TI - A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence JO - J Biol Chem VL - 275 UR - https://doi.org/10.1074/jbc.M004424200 DO - 10.1074/jbc.M004424200 ID - Carroll2000 ER - TY - JOUR AU - Watts, C. K. AU - Sweeney, K. J. AU - Warlters, A. AU - Musgrove, E. A. AU - Sutherland, R. L. PY - 1994 DA - 1994// TI - Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells JO - Breast Cancer Res Treat VL - 31 UR - https://doi.org/10.1007/BF00689680 DO - 10.1007/BF00689680 ID - Watts1994 ER - TY - JOUR AU - Foster, J. S. AU - Henley, D. C. AU - Bukovsky, A. AU - Seth, P. AU - Wimalasena, J. PY - 2001 DA - 2001// TI - Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function JO - Mol Cell Biol VL - 21 UR - https://doi.org/10.1128/MCB.21.3.794-810.2001 DO - 10.1128/MCB.21.3.794-810.2001 ID - Foster2001 ER - TY - JOUR AU - Zwijsen, R. M. AU - Wientjens, E. AU - Klompmaker, R. AU - Sman, J. AU - Bernards, R. AU - Michalides, R. J. PY - 1997 DA - 1997// TI - CDK-independent activation of estrogen receptor by cyclin D1 JO - Cell VL - 88 UR - https://doi.org/10.1016/S0092-8674(00)81879-6 DO - 10.1016/S0092-8674(00)81879-6 ID - Zwijsen1997 ER - TY - JOUR AU - Dean, J. L. AU - Thangavel, C. AU - McClendon, A. K. AU - Reed, C. A. AU - Knudsen, E. S. PY - 2010 DA - 2010// TI - Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure JO - Oncogene VL - 29 UR - https://doi.org/10.1038/onc.2010.154 DO - 10.1038/onc.2010.154 ID - Dean2010 ER - TY - STD TI - Jessen BA, Lee L, Koudriakova T, Haines M, Lundgren K, Price S, et al. Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors. J Appl Toxicol. 2007;133–142. ID - ref61 ER - TY - JOUR AU - Fornier, M. N. AU - Rathkopf, D. AU - Shah, M. AU - Patil, S. AU - O’Reilly, E. AU - Tse, A. N. PY - 2007 DA - 2007// TI - Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-1218 DO - 10.1158/1078-0432.CCR-07-1218 ID - Fornier2007 ER - TY - JOUR AU - Lam, L. T. AU - Pickeral, O. K. AU - Peng, A. C. AU - Rosenwald, A. AU - Hurt, E. M. AU - Giltnane, J. M. PY - 2001 DA - 2001// TI - Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol JO - Genome Biol VL - 2 UR - https://doi.org/10.1186/gb-2001-2-10-research0041 DO - 10.1186/gb-2001-2-10-research0041 ID - Lam2001 ER - TY - JOUR AU - Shapiro, G. I. PY - 2006 DA - 2006// TI - Cyclin-dependent kinase pathways as targets for cancer treatment JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.03.7689 DO - 10.1200/JCO.2005.03.7689 ID - Shapiro2006 ER - TY - JOUR AU - Sausville, E. A. AU - Arbuck, S. G. AU - Messmann, R. AU - Headlee, D. AU - Bauer, K. S. AU - Lush, R. M. PY - 2001 DA - 2001// TI - Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms JO - J Clin Oncol VL - 19 ID - Sausville2001 ER - TY - JOUR AU - Kortmansky, J. AU - Shah, M. A. AU - Kaubisch, A. AU - Weyerbacher, A. AU - Yi, S. AU - Tong, W. PY - 2005 DA - 2005// TI - Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.03.116 DO - 10.1200/JCO.2005.03.116 ID - Kortmansky2005 ER - TY - JOUR AU - Ma, C. X. AU - Ellis, M. J. AU - Petroni, G. R. AU - Guo, Z. AU - Cai, S. R. AU - Ryan, C. E. PY - 2013 DA - 2013// TI - A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer JO - Breast Cancer Res Treat VL - 137 UR - https://doi.org/10.1007/s10549-012-2378-9 DO - 10.1007/s10549-012-2378-9 ID - Ma2013 ER - TY - JOUR AU - Noble, M. E. AU - Endicott, J. A. PY - 1999 DA - 1999// TI - Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies JO - Pharmacol Ther VL - 82 UR - https://doi.org/10.1016/S0163-7258(98)00051-5 DO - 10.1016/S0163-7258(98)00051-5 ID - Noble1999 ER - TY - JOUR AU - Toogood, P. L. AU - Harvey, P. J. AU - Repine, J. T. AU - Sheehan, D. J. AU - VanderWel, S. N. AU - Zhou, H. PY - 2005 DA - 2005// TI - Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 JO - J Med Chem VL - 48 UR - https://doi.org/10.1021/jm049354h DO - 10.1021/jm049354h ID - Toogood2005 ER - TY - STD TI - Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;1427–38. ID - ref70 ER - TY - JOUR AU - Schwartz, G. K. AU - LoRusso, P. M. AU - Dickson, M. A. AU - Randolph, S. S. AU - Shaik, M. N. AU - Wilner, K. D. PY - 2011 DA - 2011// TI - Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) JO - Br J Cancer VL - 104 UR - https://doi.org/10.1038/bjc.2011.177 DO - 10.1038/bjc.2011.177 ID - Schwartz2011 ER - TY - JOUR AU - Finn, R. AU - Hurvitz, S. AU - Allison, M. AU - Applebaum, S. AU - Glaspy, J. AU - DiCarlo, B. PY - 2010 DA - 2010// TI - Phase I study of PD 0332991, a novel, oral, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole, for first-line treatment of metastatic post-menopausal, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative JO - Cancer Res VL - 69 ID - Finn2010 ER - TY - JOUR AU - Finn, R. S. AU - Crown, J. P. AU - Boer, K. AU - Lang, I. AU - Parikh, R. J. AU - Breazna, A. PY - 2012 DA - 2012// TI - Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advances breast cancer (BC) JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds045 DO - 10.1093/annonc/mds045 ID - Finn2012 ER - TY - JOUR AU - Finn, R. S. AU - Crown, J. P. AU - Lang, I. AU - Boer, K. AU - Bondarenko, I. M. AU - Kulyk, S. O. PY - 2015 DA - 2015// TI - The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18). A randomised phase 2 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71159-3 DO - 10.1016/S1470-2045(14)71159-3 ID - Finn2015 ER - TY - JOUR AU - Johnson, S. M. AU - Torrice, C. D. AU - Bell, J. F. AU - Monahan, K. B. AU - Jiang, Q. AU - Wang, Y. PY - 2010 DA - 2010// TI - Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition JO - J Clin Invest VL - 120 UR - https://doi.org/10.1172/JCI41402 DO - 10.1172/JCI41402 ID - Johnson2010 ER - TY - STD TI - Pfizer’s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer. http://press.pfizer.com/press-release/pfizers-palbociclib-pd-0332991-receives-food-and-drug-administration-breakthrough-ther. Accessed January 26, 2015. UR - http://press.pfizer.com/press-release/pfizers-palbociclib-pd-0332991-receives-food-and-drug-administration-breakthrough-ther ID - ref76 ER - TY - STD TI - FDA approves Ibrance for postmenopausal women with advanced breast cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm. Accessed January 26, 2015. UR - http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm ID - ref77 ER - TY - JOUR AU - Turner, N. C. AU - Ro, J. AU - André, F. AU - Loi, S. AU - Verma, S. AU - Iwata, H. PY - 2015 DA - 2015// TI - Palbociclib in hormone-receptor-positive advanced breast cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1505270 DO - 10.1056/NEJMoa1505270 ID - Turner2015 ER - TY - STD TI - DeMichelle A, Clark AS, Tan KS, Haitian DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015 Mar 1;21(5):995-1001. ID - ref79 ER - TY - STD TI - Shapiro J, Rosen LS, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol. 2013:Suppl:abstr 2500. ID - ref80 ER - TY - STD TI - Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. LY2835219, a novel cell cycle inhibitor selective for CDK 4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. J Clin Oncol. 2014;Suppl:abstr 534. ID - ref81 ER - TY - JOUR AU - Tolaney, S. M. AU - Rosen, L. S. AU - Beeram, M. AU - Goldman, J. W. AU - Gandhi, A. W. AU - Papadopoulos, K. P. PY - 2015 DA - 2015// TI - Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/1538-7445.SABCS14-P5-19-13 DO - 10.1158/1538-7445.SABCS14-P5-19-13 ID - Tolaney2015 ER - TY - JOUR AU - Infante, J. R. AU - Shapiro, G. I. AU - Witteveen, P. O. AU - Gerecitano, J. F. AU - Ribrag, V. AU - Chugh, R. PY - 2013 DA - 2013// TI - Phase I multicenter, open label, dose-escaltaion study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.TARG-13-A276 DO - 10.1158/1535-7163.TARG-13-A276 ID - Infante2013 ER -